Highlight Therapeutics
Spain - Valencia
BiotechnologyFocus: Immuno-oncology, synthetic dsRNA complex
Highlight Therapeutics is a life sciences company focused on Immuno-oncology, synthetic dsRNA complex.
OncologyGene Therapy
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
Part 1: BO-112
CancerClinical Trials (1)
NCT02828098Exploratory Study of BO-112 in Adult Patients With Aggressive Solid Tumors
Phase 1Nanoplexed Poly I:C BO-112
Advanced Hepatocellular CarcinomaClinical Trials (1)
NCT04777708BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer
Phase 1Definitive Surgical Resection
LeiomyosarcomaClinical Trials (1)
NCT04420975Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
Phase 1BO-112 in combination with ablative radiotherapy
Non-Small Cell Lung Cancer MetastaticClinical Trials (1)
NCT05265650Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC
Phase 1/2BO-112 plus pembrolizumab
MelanomaClinical Trials (1)
NCT04570332BO-112 With Pembrolizumab in Unresectable Malignant Melanoma
Phase 2Hepatic Biopsy
Colorectal CancerClinical Trials (1)
NCT04508140Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis
Phase 2BO-112
Basal Cell CarcinomaClinical Trials (1)
NCT06422936Clinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC)
Phase 2Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Founded: 2024
Portfolio: 7 clinical trials
Top TAs: Oncology
Publications: 8 in PubMed